Date: 2012-06-15
Type of information:
phase: 2
Announcement:
Company: Glycotope (Germany)
Product: PankoMab™
Action mechanism: PankoMab-GEX™ is based on Glycotope’s unique and proprietary GlycoBodies™ technology and recognizes carbohydrate based tumor epitopes. This humanized and tumor-specific antibody is particularly suitable for e.g. ovarian and lung cancers and binds to over 90% of cases in several solid cancer indications. PankoMab-GEX™ expresses a series of potent anti-tumor modes of action strongly enhanced by glycooptimization through Glycotope’s GlycoExpress™ platform. This allows significantly improved treatment outcome compared to non-glycooptimized biotherapeutics. Preliminary results of the Phase I studies of PankoMab™ show very good tolerability, no significant toxicity and strong signals for high anti-tumor activity and specificity.
Disease: ovarian cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: Glycotope, a german company focused on the development of innovative antibodies for the treatment of various cancer types, targeting glycostructures on cell surfaces and of so-called BioBetters, recombinant biopharmaceuticals with optimized and fully human sugar structures, has announced that it will move its glycooptimized therapeutic antibody PankoMab™ to Phase II of clinical development in ovarian cancer with further indications planned to follow.